|1.||Chen, Min: 55 articles (11/2015 - 11/2002)|
|2.||Kallenberg, Cees G M: 50 articles (01/2016 - 01/2002)|
|3.||Zhao, Ming-Hui: 49 articles (12/2015 - 05/2004)|
|4.||Guillevin, Loïc: 46 articles (12/2015 - 10/2004)|
|5.||Falk, Ronald J: 46 articles (04/2015 - 01/2002)|
|6.||Specks, Ulrich: 44 articles (07/2015 - 05/2002)|
|7.||Jennette, J Charles: 40 articles (06/2015 - 01/2002)|
|8.||Stegeman, Coen A: 32 articles (01/2016 - 01/2002)|
|9.||Gross, W L: 31 articles (05/2014 - 01/2000)|
|10.||Heeringa, Peter: 28 articles (01/2016 - 10/2002)|
03/01/2013 - "3) The ANCA test is highly specific for these types of autoimmune vasculitides but renal biopsy still remains the gold standard for final diagnosis, prognostic evaluation and therapeutic intervention, although discrepancy between clinical and morphological features is frequently found. "
12/01/2007 - "Most patients with PTU-associated ANCA-positive vasculitis had good outcomes; however, severe cases existed. "
01/01/2004 - "Furthermore, the yield of antineutrophil cytoplasmic antibody testing can be improved by the use of a well-standardized test, adherence to published guidelines, and restricting the use of the tests to clinical situations with a rather high pretest probability for antineutrophil cytoplasmic antibody-associated vasculitides. "
07/01/2002 - "These results show that ANCA-positive vasculitis patients have high sFas levels and that the levels remain elevated even in clinical remission. "
05/01/2000 - "Despite the improved outcome of patients with ANCA vasculitis in the recent decade, their long-term prognosis continues to be primarily determined by a rapid diagnosis, and the prompt institution of therapy."
|2.||Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
01/01/2012 - "Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysis."
12/01/2010 - "Current remission maintenance therapies for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) are limited by partial efficacy and toxicity. "
11/01/2006 - "Increased T cell activation in patients with ANCA-associated vasculitis in remission during and after immunosuppressive treatment is associated with persistent or renewed ANCA positivity."
03/01/2003 - "Serial measurements of PR3- and MPO-ANCA titers in patients with ANCA-associated vasculitis during remission can help predict relapses, and preemptive increases in immunosuppression following fourfold titer rises reduces the risk of relapses. "
06/01/2015 - "Recent data from randomized controlled clinical trials have allowed the development of recommendations for treatment of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitides (AAV). "
01/01/2011 - "High-dose steroid therapy is very effective for ANCA-related glomerulonephritis. "
01/01/2007 - "When judging relapse and remission in ANCA-associated glomerulonephritis, it is important to evaluate the overall clinical findings and histopathological findings in addition to the serial ANCA titers."
05/01/2000 - "The next millennium will be marked by improved prognosis for ANCA-negative glomerulonephritis compared with that observed with this devastating disease in past decades."
04/01/2015 - "Future studies will try to determine if and how renal histology could be helpful in guiding treatment of ANCA-associated glomerulonephritis. "
04/01/2015 - "Improved prognosis in Norwegian patients with glomerulonephritis associated with anti-neutrophil cytoplasmic antibodies."
|4.||Wegener Granulomatosis (Wegener's Granulomatosis)
05/01/1993 - "The identification of a new serologic marker, cytoplasmic pattern antineutrophil cytoplasmic autoantibody (C-ANCA), allows for the early diagnosis of Wegener's granulomatosis and gives the patient the best chance for remission with cytotoxic therapy. "
10/01/1999 - "The conclusion is that antineutrophil cytoplasmic antibodies status can be a very useful diagnostic adjunct to the evaluation of patients with suspected Wegener's granulomatosis, but is not a substitute for clinical expertise and histopathologic data during the course of providing patient care. "
03/01/1994 - "In cases of Wegener's granulomatosis with salivary symptoms, measurement of salivary gland functional capacity, in addition to the c-ANCA test, may help to monitor disease activity. "
01/01/1993 - "If ANCA-tests are failing in patients with Wegener's granulomatosis or microscopic polyarteritis, markers of activated coagulation are helpful in evaluation of disease activity. "
01/01/1992 - "Serial ANCA titers reverted to normal in only two of the four patients with Wegener's granulomatosis who attained clinical remission. "
05/01/1996 - "Regardless of whether they are pathogenic, sequential measurement of anti-neutrophil cytoplasmic antibody titres have proved extremely useful in the management of patients with systemic vasculitis. "
07/01/1991 - "It is concluded that ANCA are very helpful in the diagnosis of systemic vasculitis, notably in cases with first-time alveolar haemorrhage. "
12/01/2008 - "Monocytes have been shown to be activated in ANCA-positive systemic vasculitis, but their state of activation in clinical remission is unknown.Fifteen"
11/01/2006 - "Remission in antineutrophil cytoplasmic antibody-associated systemic vasculitis."
01/01/1994 - "A rise in antineutrophil cytoplasmic antibody in a patient with systemic vasculitis in remission."
|1.||Antineutrophil Cytoplasmic Antibodies (ANCA)
|5.||glucuronyl glucosamine glycan sulfate (Vessel)
|6.||Adrenal Cortex Hormones (Corticosteroids)
|8.||Myeloblastin (Proteinase 3)
|4.||Renal Dialysis (Hemodialysis)